Despite being mixed, Fresenius’ Q1 report looks a bit uninspiring, which is not bad as the world creaks under the weight of the virus. But not very things is running perfectly. Kabi’s issues seem to have worsened, which legitimises the CEO change ex-post. Unfortunately, management was not too good at providing many details about the cost-cutting programme.
Figures were a notch above our expectations and slightly above street expectations (top line: +1%; adjusted EBITDA: +2%).
Companies: Fresenius SE & Co. KGaA
As we had already speculated at a recent target price change (on 05/02/2021), the announced departure of Dr Krick, Fresenius’ dinosaur, could trigger some changes. The first ‘victim’ may be the head of Kabi and we clearly expect more to come. In essence, this could signal to the capital markets that there is something already set in motion. This might change sentiment towards Fresenius as we still see the share is clearly undervalued.
We had been really surprised by the announcement of a cost-cutting programme, which is expected to give Fresenius a nice profitability push by the end of 2023. This is earlier than FMC’s. However, we do not really believe in a coincidence as Fresenius’ management should be the master of the ceremonies but, interestingly, it could be able to achieve this.
The Q4 figures have beaten our cautious expectations as we had taken some provisions into account. Updated consensus was unavailable.
Fresenius’ broad portfolio stabilised the top-line and earnings but the picture has been mixed not just among the divisions. Interestingly this has also proved true on an intra-divisional basis in that the trends have followed the pandemic. The Q3 figures showed some relief, especially in Helios Spain.
The reported figures were a notch weaker than expected, but broadly met consensus.
Fresenius’ business model has shown to be quite resilient, but some businesses did better than others, which looks quite normal to us. However, Helios’ Spanish business seems to have a bit of a cold as its profitability has substantially deteriorated. This could be a communication issue, but we do not fully understand the reason.
Reported figures were a notch better than expected, but consensus was beaten (+3% to 5%). Adjusted for potential pandemic-related effects, FY guidance was lowered.
Despite the unquantified pandemic related costs, Fresenius was able to protect earnings (not margin). This was a bit unexpected as we had factored in some higher extra costs, especially in the clinics’ business and at Kabi. The latter also did better. All in all, the reported figures were stronger than expected.
We appreciate management’s qualitative approach to clarify potential impacts unless figures are available.
Fresenius’ figures were characterised by the mixed developments at FMC and Kabi. The latter division started to face a stronger impact from intensifying competition in North America. This had been expected, but kicked in more strongly than expected. Helios’ performance was in line. All in all, the figures were above our expectations, whereas consensus was broadly met.
We have envisaged for quite a while that Kabi will have to leave its IV drug Shangri La. This has now happened. Should one worry about this? The Q3 figures show that other segments could cushion the effects of greater competition in this segment to a certain extent. What looks more interesting is what is going on in the clinic business where some clouds are gathering over the sun (Helios). Or is it just a penumbral solar eclipse?
Fresenius’ Q2 figures benefited from good organic growth across all divisions, but profitability development showed a mixed picture. Kabi was a (still) positive surprise, Helios moderated as expected and FMC was hit by various expected as well as unexpected issues. Vamed became a small but shining star. Reported figures were more or less in line with our expectations and consensus was also broadly met. The higher top-line guidance is quite nice, but profitability is barely expected to follow.
Fresenius reported a strong set of figures, which confirmed our view. Consensus was beaten. Kabi continued to generate profitable growth and Helios signalled some positive developments in Germany and strong organic sales growth in Spain.
Fresenius’s Q4 figures were pretty much in-line with our expectations adjusted for our too low assumption on FMC, as Helios came in stronger than expected, but Kabi a notch weaker. Consensus was also broadly met.
US pharma giant Pfizer announced that the issues at its sterile injectables plan in Kansas could be solved by the end of 2019 as constant supply could not be maintained after a warning letter from the FDA in 2017.
Fresenius could not re-switch the light of strong growth. The full Q3 figures did nothing to change our past view on the company’s strong growth, but was good enough to light a candle. The increased detail was helpful in gaining a better understanding of the potential Q4 outcome, which we expect to be fairly positive.
The released preliminary Q3 did not fully match our expectations but neither did it destroy our view of the company. However, Fresenius reported some internal issues (e.g. Helios), which caused management to narrow its previously-given guidance to the lower end. The full set of figures will be reported on 30 October 2018.
Today the Delaware court upheld the termination of the merger agreement with Akorn.
Research Tree provides access to ongoing research coverage, media content and regulatory news on Fresenius SE & Co. KGaA Sponsored ADR.
We currently have 0 research reports from 0
OptiBiotix has reported its final results for the year to December 2020, which are largely in-line with the financials reported with the recent ‘Strategy and commercial update'. 2020 was a strong year for the company as its two operational divisions achieved EBITDA profitability supported by increased commercialisation of the group's product range. This commercial moment has continued into 2021, as the company looks to scale its first-generation product sales with new product lines and new terri
Companies: OptiBiotix Health PLC
CareTech is a specialist social care and educational services provider. This morning, the group has announced interim results to 31 March 2021, which illustrate another positive six month period, particularly when considering the present wider backdrop. An increase in underlying PBT of 31.6% against the prior year benefited from organic growth, as well as the acquisition of Smartbox, transfer in of The Huntercombe Group facilities and a full period contribution from the Middle East. As reported
Companies: CareTech Holdings PLC
As midsummer’s day looms (where has this year gone?), there is greater optimism, in general, than may have been anticipated a few months ago. A post-pandemic, ‘vaccine-driven’ recovery demonstrated by increased consumer spending as lockdown measures are lifted has been one of the catalysts. The FTSE 100 has been range-bound in the last month 6,900-7,100. We have seen a combination of broadly positive company results across a range of sectors, further examples of M&A activity and a sequence of ne
Companies: AMYT ARBB ARW BAG BEG BONH BWNG CWK DNK EML EPWN FBD FA/ GPH GSF GNC HUW IGC INSE KAPE KP2 MMAG NRR NESF OTMP ROL RUA SEN SUR TON TOU TXP TGL VLS WINK
Evgen reported full-year results to 31 March that were c.£0.3m better than expected, with an adjusted net loss of £2.8m resulting in year-end cash of £11.6m (FC est. £11.3m), which provides a cash runway to at least mid-2023. The company continues to progress SFX-01 in glioma (brain cancer) and metastatic breast cancer (mBC) pre-clinical models, with the aim of commencing a Phase Ib/II trial in Q2 2022 (glioma) and potentially a Phase IIb trial in mBC patients who have become resistant to first-
Companies: Evgen Pharma Plc
Further to yesterday's announcement, NetScientific, the international life sciences and sustainability technology investment and commercialisation group, has announced that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), is to issue c.5.3m new shares of common stock to raise gross proceeds of c.$45m. NetScientific currently owns 1,278,000 shares of PDS' common stock, representing 5.7% of its fully diluted share capital prior to the issue.
Companies: NetScientific plc
The UK market showed a continued recovery in the first quarter albeit the indices are still well short of their all-time peaks, unlike many of their international peers. The FTSE 100 has risen by 1,186 points (21.4%) since the end of October and the FTSE 250 by 4,304 points (25.0%). The comparable performance since the start of the year is less spectacular- the FTSE 100 has risen by 253 points (3.9%) and the FTSE 250 has risen by 1,070 points (5.0%). The factors behind the sustained rally are fa
Companies: AMYT ARBB CEG BAG BVC BEG BONH BLVN BRSD CML CWK CRPR EYE ECHO FDM FAR FA/ GPH GSF HUW INSE JDG KAPE KP2 MACF MPAC MNZS NESF NBI OTMP OBD PREM QFI RUA SCS SEN SOS SUR TON TOU TXP TGL TCN UEM VLS WYN
AVO’s goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly derisked the project. Now, AVO is working on the verification and validation phase, prior to LIGHT being used on the first patients to support CE marking. In its recent technical update, the company highlighted progress made over the past three months towards a ful
Companies: AVO ARBB ARIX BBGI CLIG DNL FLTA ICGT OCI PCA PIN RECI STX SPO SCE TRX VTA
Trading has strengthened significantly since restrictions eased in April, especially in the UK. UK brand sales are now up 64% YTD (+18% vs 2019). Further distribution gains are being made, including in the USA and online sales have tripled, albeit off a small base. Net cash has increased to £6.6m (Dec’20, £4.9m). Risk appears to lie to the upside vs prudent forecasts. The re-rating looks well supported to us, and we look forward to the H1 update in July
Companies: Warpaint London PLC
Calnex Solutions has announced record results for FY21 following customer orders up across all product types and within all regions, with FY21 revenue up 31% to £18.0m and adjusted PBT up 43% to £5.1m. Calnex has firmly established a trusted reputation worldwide, launching multiple first to market telecoms and network testing solutions. Calnex continues to accelerate its investment in R&D and expand its product roadmap, adding increased engineering, sales and customer support capacity in order t
Companies: Calnex Solutions Plc
SDI Group has published a second positive trading update ahead of July’s FY21E results announcement. Management’s guidance for revenue and adjusted PBT is approximately £35.3m and £7.4m respectively, ahead of our previous FY21E estimates (and previous guidance) of £34.0m and £6.7m. We upgrade our FY21E forecasts accordingly, with a 10% uplift to our fully adjusted PBT forecast. Current base guidance for FY22E remains unchanged with revenue of £42m and adjusted PBT of £8.7m. Consequently, we are
Companies: SDI Group plc
Venture Life Group has announced the acquisition of BBI Healthcare, a leading Women's Health and Energy Management/Diabetes company. Venture Life will pay up to £36.0m for the business, which generated revenues of £10.2m and adjusted EBITDA of £2.6m in FY20A. We believe the acquisition will fit well within Venture Life, significantly expanding the group's own brand revenues and providing a number of revenue growth and operational leverage opportunities. The acquisition has been financed by exist
Companies: Venture Life Group Plc
In an encouraging sign of building US momentum, Yourgene has announced it has signed a multi-year licence and supply agreement with a major US precision medicine company to enable it to offer a new reproductive health screening service from its own laboratories. The agreement encompasses a non-exclusive licence to Yourgene’s proprietary bioinformatics Flex analysis software and a supply agreement for sample preparation reagents and instrumentation. Notably, this includes the Ranger sample enrich
Companies: Yourgene Health Plc
NetScientific, the international life sciences and sustainability technology investment and commercialisation group, has announced that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has itself announced (after trading hours 14 June) that it is commencing an underwritten public offering of shares of its common stock. PDS intends to use a portion of the net proceeds for the development of its clinical pipeline and the balance for general corporate / working capital purposes.
The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and soc
Companies: VSC ABT ABBV AFMD A GOOGL AMGN AZN BCART BMY EKTAB EXAS GSK ILMN IPH ISRG IBAB JNJ MDXH MDG1 MDT MRK MYGN NSTG NOVN OCX PFE RAYB ROG SAN SGEN TMO TNG VAR VCYT VNRX XNCR ECX IMM
In line with the recent FCA announcement, Venture Life, in conjunction with its auditor has taken the decision to delay the release of its FY19 results, though the company notes it was in position to release them. Also, with this announcement, the group has provided a strong trading update, noting that all business units are still operating as of now. Specifically, Venture Life points to orders of over €7m from its Dentyl partner in China for 2020 (versus €0.5m for 2019), with at least €2m for d